Medical News

RSS

Mayo Clinic research ends major controversy in cancer research

ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.

6 Jan 2010

NCD to hear presentations and discuss the state of wounded warrior care and transition

The National Council on Disability (NCD), as part of its 2.5 day quarterly meeting, will hear presentations and discuss the state of wounded warrior care and transition. Presenters from the Fort Hood and Fort Sam Houston Center for the Intrepid will provide their perspective.

6 Jan 2010

ORNL story tips for January 2010

World-class computing at Oak Ridge National Laboratory could be unleashed to save as much as $50 billion per year in fraud, waste and abuse in the nation's health care system.

6 Jan 2010

Ensemble Discovery initiates strategic alliance with Pfizer

Ensemble Discovery today announced the initiation of a strategic alliance with Pfizer Inc. to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.

6 Jan 2010

Physicians perform first implantation of leadless cardiac monitoring device for detecting arrhythmias

BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the first implantations of BIOTRONIK’s new leadless cardiac monitoring device performed by a team of physicians led by Professor Dr. Gerhard Hindricks, Director, Electrophysiology Department at the Leipzig Heart Center in Leipzig, Germany.

6 Jan 2010

First Edition: January 6, 2010

Today's headlines detail Democrat's intraparty efforts to finalize a health reform bill and the key policy issues at the heart of those negotiations.

6 Jan 2010

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.

6 Jan 2010

CSHL scientist discovers how bookmarking protein triggers leukemia

Each cell inherits genes from its parent as well as epigenetic information - what amounts to an instruction manual that specifies which genes should be activated or "expressed," when and to what level.

6 Jan 2010

New technique offers a low-cost alternative to make 'micromotors' for surgical instruments

Researchers at Purdue University have created a magnetic "ferropaper" that might be used to make low-cost "micromotors" for surgical instruments, tiny tweezers to study cells and miniature speakers.

6 Jan 2010

HealthSpring establishes its presence on popular social media site Facebook

Medicare plan HealthSpring today became the first major Medicare Advantage plan to establish a presence on popular social media site Facebook.

6 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

LifeVantage receives formal approval to launch Protandim in Mexico

LifeVantage Corporation, the maker of science-based solutions to oxidative stress, announced today that the Company has received formal approval from the Mexican government to launch its flagship product, Protandim®, in Mexico. Initial shipments have cleared customs and Protandim® has been shipped to distributors in Mexico.

6 Jan 2010

Toxic chemicals make us susceptible to a wide range of diseases

From the Industrial Revolution and onward, the world has become an environment that is overflowing with dangerous toxins. Mass manufacturing has resulted in thousands of chemical pollutants being released in the atmosphere, water, and soil. As well, there has been a widespread increase of chemicals being added to almost every type of food and retail product.

6 Jan 2010

Medicare beneficiaries can switch their coverage during open enrollment, says Allsup

Medicare annual enrollment ended Dec. 31, but some beneficiaries can switch their coverage during open enrollment from Jan. 1 to March 31, according to Allsup, a nationwide provider of Social Security disability representation and Medicare services.

6 Jan 2010

International Headache Society publishes new guidelines to stimulate more research on headache treatment

If you're one of the millions of headache sufferers around the world, more effective relief might be on the way in years to come. That's because the International Headache Society has just published new research guidelines intended to stimulate more research into headache treatment, and to provide researchers with guidelines to cut health risks associated with treatment.

6 Jan 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010

Renowned ophthalmologist performs innovative procedure on patient suffering from severe visual impairment

Ten years ago, Southern Californian resident Kenny Atkins suffered from severe visual impairment caused by coning of the cornea, otherwise known as keratoconus. Prescription glasses and contact lenses proved to be ineffective, and Atkins needed a solution fast – as an ocean lifeguard, Atkins’ ability to see could mean the difference between life and death.

6 Jan 2010

Making too much -- and too little -- to benefit from health care changes

Kaiser Health News staff writer Rick Schmitt, in collaboration with the Philadelphia Inquirer, writes about how the high cost of health coverage may still prevent people from benefiting from pending health care overhaul legislation.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

Medical News

Mayo Clinic research ends major controversy in cancer research

NCD to hear presentations and discuss the state of wounded warrior care and transition

ORNL story tips for January 2010

Ensemble Discovery initiates strategic alliance with Pfizer

Physicians perform first implantation of leadless cardiac monitoring device for detecting arrhythmias

First Edition: January 6, 2010

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

CSHL scientist discovers how bookmarking protein triggers leukemia

New technique offers a low-cost alternative to make 'micromotors' for surgical instruments

HealthSpring establishes its presence on popular social media site Facebook

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

LifeVantage receives formal approval to launch Protandim in Mexico

Toxic chemicals make us susceptible to a wide range of diseases

Medicare beneficiaries can switch their coverage during open enrollment, says Allsup

International Headache Society publishes new guidelines to stimulate more research on headache treatment

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Renowned ophthalmologist performs innovative procedure on patient suffering from severe visual impairment

Making too much -- and too little -- to benefit from health care changes

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News